Brexit, AIFA on non compliant MAs
Following the exit of the United Kingdom from the European Union, the Italian Medicine Agency has informed that for medicinal...
New EFSA regulation for transparency
The new Regulation EU 2019/1381, also known as “Transparency Regulation”, applicable as of 27 March 2021, will introduce important changes...
The Italian Payback, why it is so important to contain pharmaceutical expenditure
The payback system is a mechanism introduced in Italy to collect financial resources to support pharmaceutical expenditure and contain the...
IVDR, NB designation delayed
The application date of the IVD Regulation 2017/746 is still long to come but, in the meantime, progresses are being...
Environmental labelling for packaging: mandatory requirement in Italy
Since last September, in Europe, environmental labelling for packaging is mandatory for products intended for the final consumers. This new...
Updates on environmental packaging labelling
Law Decree 3 December 2020, no. 183 (the so called “Milleproroghe 2021”) was published in the Italian Official Journal on...
Updated report on biosimilar expense and consumption
The Italian Agency Medicine has made available the updated reports on themonitoring of biosimilar expense and consumption for the period...
EMA committed on medicines and vaccines development
The European Medicine Agency (EMA) has adopted a series of procedures to speed up the approvals of treatments and vaccines...
Disinfectant products authorised as PMCs
When buying a disinfectant product, as it is often the case in these days, one should always read its label...
Natural vs. safe, the regulation on botanicals
“Natural” does not necessarily means “safe”; yet, many consumers perceive the use of dietary products and food supplements based on...